Parametric Portfolio Associates LLC reduced its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 9.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 242,643 shares of the company’s stock after selling 24,331 shares during the quarter. Parametric Portfolio Associates LLC owned 0.28% of IDEXX Laboratories worth $37,729,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. D.A. Davidson & CO. grew its stake in shares of IDEXX Laboratories by 160.4% during the second quarter. D.A. Davidson & CO. now owns 625 shares of the company’s stock valued at $100,000 after buying an additional 385 shares during the last quarter. Sun Life Financial INC grew its stake in shares of IDEXX Laboratories by 9,085.7% in the second quarter. Sun Life Financial INC now owns 643 shares of the company’s stock worth $104,000 after purchasing an additional 636 shares during the last quarter. BB&T Investment Services Inc. bought a new stake in shares of IDEXX Laboratories in the second quarter worth about $104,000. Zions Bancorporation bought a new stake in shares of IDEXX Laboratories in the third quarter worth about $162,000. Finally, Coastline Trust Co bought a new stake in shares of IDEXX Laboratories in the second quarter worth about $202,000. 86.61% of the stock is currently owned by hedge funds and other institutional investors.
In other news, CEO Jonathan W. Ayers sold 18,000 shares of IDEXX Laboratories stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $148.35, for a total transaction of $2,670,300.00. Following the completion of the transaction, the chief executive officer now directly owns 1,064,573 shares in the company, valued at $157,929,404.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Jonathan W. Ayers sold 54,000 shares of IDEXX Laboratories stock in a transaction that occurred on Tuesday, November 7th. The shares were sold at an average price of $151.32, for a total transaction of $8,171,280.00. Following the transaction, the chairman now owns 1,064,573 shares of the company’s stock, valued at $161,091,186.36. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 130,160 shares of company stock worth $20,019,685. Insiders own 2.77% of the company’s stock.
Several analysts recently issued reports on the company. BidaskClub raised IDEXX Laboratories from a “sell” rating to a “hold” rating in a research note on Friday, January 5th. Aegis reissued a “sell” rating on shares of IDEXX Laboratories in a research note on Friday, December 8th. Zacks Investment Research raised IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 target price on the stock in a research note on Tuesday, October 24th. Stifel Nicolaus reissued a “buy” rating and issued a $185.00 target price on shares of IDEXX Laboratories in a research note on Tuesday, October 24th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $180.00 target price on shares of IDEXX Laboratories in a research note on Friday, October 6th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $173.67.
IDEXX Laboratories, Inc. (NASDAQ:IDXX) traded up $1.73 during trading on Friday, reaching $173.24. The company’s stock had a trading volume of 632,940 shares, compared to its average volume of 477,798. The company has a debt-to-equity ratio of -12.48, a quick ratio of 0.77 and a current ratio of 0.95. The company has a market cap of $15,100.00, a PE ratio of 56.25, a price-to-earnings-growth ratio of 2.31 and a beta of 0.42. IDEXX Laboratories, Inc. has a fifty-two week low of $116.54 and a fifty-two week high of $173.82.
IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, October 31st. The company reported $0.79 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.05. The business had revenue of $492.00 million for the quarter, compared to analysts’ expectations of $492.94 million. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. The business’s revenue was up 9.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.62 EPS. equities analysts forecast that IDEXX Laboratories, Inc. will post 3.24 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “IDEXX Laboratories, Inc. (NASDAQ:IDXX) Position Trimmed by Parametric Portfolio Associates LLC” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/13/idexx-laboratories-inc-idxx-holdings-lessened-by-parametric-portfolio-associates-llc.html.
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.